

CardiacSense Ltd – June 2021 report

1. The watch

a. Good news: Shipments of first watches (Demo watches) to our distributors has started!

These watches are used for:

- Familiarity of distributors with our watch
- Local registration of the watch in each territory

Following this, we expect to start getting purchase orders for watches.

b. We are manufacturing watches for both commercial and development purposes, and in parallel massive R&D effort is conducted for software (including mobile and cloud) upgrades.

c. We are running several lab tests needed for regulatory needs. Some are already finished successfully (such as biocompatibility)

1.

2. Clinical trials: a lot of activity in this field

a. Blood Pressure

There are two clinical trials for this indication. Both are conducted in Israel. The first one started this week, and the second (conducted at Ichilov Intensive Care Unit) is expected to be resumed in the coming month.

Following successful trials, we will start a trial in the US that will be submitted to CE and FDA

b. Oxygen saturation - SpO2

This trial was conducted in USA last week. Our engineers traveled to San Francisco to run the test. From our initial preliminary analysis results look good. We are waiting for the official results that will be provided to us from the institute that conducted the trial.

c. Heart Arrhythmias

This study is continuing in Rambam hospital (in Israel) and data is accumulated for algorithm



improvement. Following a successful trial, we will start a trial that will be submitted to CE & FDA

3. R&D:

- a. Massive R&D effort is done in many fields: hardware improvements, software coding, quality assurance, algorithm writing and improvement and many more.
- b. This month we have started activity in the field of Artificial Intelligence. This is for sleep analysis first and early warning later

4. Commercial: a lot of activities in this field.

- 2. Discussion with 2 leading global companies is in process as well as with other various companies. We will update once it will mature to a signed agreement.

5. Finance:

- a. The round of \$90M pre-money which is the pre-IPO was finished last month.
- b. We are planning to submit the 3rd draft of prospectus to the Israel Securities Authority (ISA) until the end of the month.